BR112014010407A2 - compostos de azetidina, composições e seu uso como inibidores de hidrolase de epóxido solúvel - Google Patents

compostos de azetidina, composições e seu uso como inibidores de hidrolase de epóxido solúvel

Info

Publication number
BR112014010407A2
BR112014010407A2 BR112014010407A BR112014010407A BR112014010407A2 BR 112014010407 A2 BR112014010407 A2 BR 112014010407A2 BR 112014010407 A BR112014010407 A BR 112014010407A BR 112014010407 A BR112014010407 A BR 112014010407A BR 112014010407 A2 BR112014010407 A2 BR 112014010407A2
Authority
BR
Brazil
Prior art keywords
compositions
epoxide hydrolase
soluble epoxide
hydrolase inhibitors
compounds
Prior art date
Application number
BR112014010407A
Other languages
English (en)
Inventor
Guérot Carine
Knust Henner
M Ceccarelli Simona
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112014010407A2 publication Critical patent/BR112014010407A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine

Abstract

resumo compostos de azetidina, composições e seu uso como inibidores de hidrolase de epóxido solúvel são providos compostos de fórmula i, estereoisômeros, tautômeros e sais farmaceuticamente aceitáveis dos mesmos, em que a, l1, l2, r1 e r2 são definidos aqui, uma composição farmacêutica e métodos de utilizar esses compostos como inibidores de hidrolase de epóxido solúvel. r1-l1-a-l2-r2 1/1
BR112014010407A 2011-11-01 2012-10-29 compostos de azetidina, composições e seu uso como inibidores de hidrolase de epóxido solúvel BR112014010407A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11187364 2011-11-01
PCT/EP2012/071405 WO2013064467A1 (en) 2011-11-01 2012-10-29 Azetidine compounds, compositions and their use as inhibitors of soluble epoxide hydrolase

Publications (1)

Publication Number Publication Date
BR112014010407A2 true BR112014010407A2 (pt) 2017-04-25

Family

ID=47143085

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010407A BR112014010407A2 (pt) 2011-11-01 2012-10-29 compostos de azetidina, composições e seu uso como inibidores de hidrolase de epóxido solúvel

Country Status (12)

Country Link
US (2) US8809552B2 (pt)
EP (1) EP2773644B1 (pt)
JP (1) JP5778353B2 (pt)
KR (1) KR101646858B1 (pt)
CN (1) CN103958516B (pt)
BR (1) BR112014010407A2 (pt)
CA (1) CA2848824A1 (pt)
ES (1) ES2580404T3 (pt)
HK (1) HK1195299A1 (pt)
MX (1) MX2014003920A (pt)
RU (1) RU2615995C2 (pt)
WO (1) WO2013064467A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN09346A (pt) * 2012-06-13 2015-07-17 Hoffmann La Roche
ES2753163T3 (es) 2012-09-25 2020-04-07 Hoffmann La Roche Derivados de hexahidropirrolo[3,4-c]pirrol y compuestos relacionados como inhibidores de la autotaxina (ATX) y como inhibidores de la producción de ácido lisofosfatídico (LPA) para tratar, por ejemplo, enfermedades renales
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
MY187449A (en) 2013-11-26 2021-09-22 Hoffmann La Roche New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
JP6554481B2 (ja) 2014-03-26 2019-07-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ オートタキシン（ａｔｘ）及びリゾホスファチジン酸（ｌｐａ）産生の阻害剤としての縮合［１，４］ジアゼピン化合物
PL3122750T3 (pl) 2014-03-26 2020-03-31 F.Hoffmann-La Roche Ag Związki bicykliczne jako inhibitory wytwarzania autotaksyny (ATX) i kwasu lizofosfatydowego (LPA)
CN111454246A (zh) * 2014-08-28 2020-07-28 X-化学有限公司 可溶性环氧化物水解酶抑制剂及其用途
NZ731118A (en) 2014-10-31 2023-05-26 Indivior Uk Ltd Dopamine d3 receptor antagonists compounds
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MX2020004504A (es) 2015-09-04 2021-11-10 Hoffmann La Roche Derivados de fenoximetilo.
AU2016328436B2 (en) 2015-09-24 2020-05-14 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
CA2991615A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
KR20180054830A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서의 이환형 화합물
CN107614505B (zh) 2015-09-24 2021-05-07 豪夫迈·罗氏有限公司 作为双重atx/ca抑制剂的新型二环化合物
AU2018233079B9 (en) 2017-03-16 2021-07-22 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as dual ATX/CA inhibitors
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
WO2019156991A1 (en) * 2018-02-06 2019-08-15 The Regents Of The University Of California Methods of inhibiting formation of alpha synuclein aggregates
WO2021102314A1 (en) * 2019-11-21 2021-05-27 University Of Utah Research Foundation Trpv4 receptor ligands
CA3181351A1 (en) * 2020-05-06 2021-11-11 Antonio Romero Nampt modulators
CN115028629A (zh) * 2021-03-04 2022-09-09 成都先导药物开发股份有限公司 一种8-苄氧羰基-2-叔丁氧羰基-2,5-双氮杂螺[3,5]壬烷的制备方法
WO2024033479A1 (en) * 2022-08-11 2024-02-15 Remynd N.V. (aza)spiroheptane derivatives for the treatment of neurodegenerative disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780468A (en) * 1987-08-07 1988-10-25 Warner-Lambert Company 8-trifluoromethyl quinolones as antibacterial agents
DE3930262A1 (de) * 1989-09-11 1991-03-21 Thomae Gmbh Dr K Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US8815951B2 (en) 1996-08-13 2014-08-26 The Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of inflammation
AU1317000A (en) 1998-10-20 2000-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Method of treating immunological disorders mediated by t-lymphocytes
CA2449486A1 (en) 2001-06-29 2003-01-09 Boehringer Ingelheim Pharmaceuticals Inc. Methods of using soluble epoxide hydrolase inhibitors
WO2005089380A2 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
US20050222252A1 (en) 2004-03-31 2005-10-06 The Regents Of The University Of California Use of cis-Epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils
US20060148744A1 (en) 2004-09-23 2006-07-06 Regents Of The University Of California Use of cis-epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce damage from stroke
JP2010507586A (ja) 2006-10-20 2010-03-11 アレテ セラピューティクス， インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
CN101535259A (zh) * 2006-10-20 2009-09-16 亚瑞特医疗公司 作为可溶性环氧化物水解酶抑制剂的苯基脲化合物
CN101563088A (zh) * 2006-12-18 2009-10-21 弗·哈夫曼-拉罗切有限公司 可溶性环氧化物水解酶的抑制剂的新用途
WO2008094869A1 (en) 2007-01-29 2008-08-07 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders
NZ584471A (en) * 2007-10-11 2012-01-12 Glaxosmithkline Llc Triazine cyclohexane carboxamide compounds and their use
US8399425B2 (en) 2007-11-08 2013-03-19 The Regents Of The University Of California Alleviating neuropathic pain with EETs and sEH inhibitors
WO2009129501A1 (en) 2008-04-18 2009-10-22 Arete Therapeutics, Inc. Use of soluble epoxide hydrolase inhibitors in the treatment of smooth muscle disorders
WO2009154132A1 (ja) * 2008-06-19 2009-12-23 萬有製薬株式会社 スピロジアミン-ジアリールケトオキシム誘導体
TW201038572A (en) * 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
CN102093320B (zh) * 2009-12-09 2013-08-28 扬子江药业集团上海海尼药业有限公司 一种可溶性环氧化物水解酶抑制剂
WO2013065712A1 (ja) * 2011-10-31 2013-05-10 東レ株式会社 ジアザスピロウレア誘導体及びその医薬用途
EP2820011A1 (en) * 2012-03-02 2015-01-07 Syngenta Participations AG Microbiocidal pyrazole derivatives

Also Published As

Publication number Publication date
RU2615995C2 (ru) 2017-04-12
JP5778353B2 (ja) 2015-09-16
ES2580404T3 (es) 2016-08-23
EP2773644A1 (en) 2014-09-10
KR101646858B1 (ko) 2016-08-08
CN103958516A (zh) 2014-07-30
HK1195299A1 (zh) 2014-11-07
EP2773644B1 (en) 2016-05-04
WO2013064467A1 (en) 2013-05-10
CA2848824A1 (en) 2013-05-10
US20130109668A1 (en) 2013-05-02
CN103958516B (zh) 2016-08-24
US8809552B2 (en) 2014-08-19
KR20140095515A (ko) 2014-08-01
JP2014534224A (ja) 2014-12-18
MX2014003920A (es) 2014-07-09
US20140323462A1 (en) 2014-10-30
US9139593B2 (en) 2015-09-22
RU2014120373A (ru) 2015-12-10

Similar Documents

Publication Publication Date Title
BR112014010407A2 (pt) compostos de azetidina, composições e seu uso como inibidores de hidrolase de epóxido solúvel
PH12020550552A1 (en) Inhibitors of hepatitis c virus
BR112013010018A2 (pt) inibidores de cdk
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
MY196427A (en) Piperidinyl Indole Derivatives And Their Use As Complement Factor B Inhibitors
BR112015022804A2 (pt) novos derivados de octahidro-pirrol [3,4-c]-pirrol e seus análogos como inibidores de autotaxina
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
EA201101026A1 (ru) Ингибиторы бета-секретазы
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
BR112012023382A2 (pt) compostos, composições e métodos de uso de imidazopiridina.
ECSP12012103A (es) Inhibidores de virus flaviviridae.
BR112014003693A2 (pt) amino quinazolinas como inibidores de quinase
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
SG195106A1 (en) Trpv4 antagonists
NI201100096A (es) Lactamas como inhibidores de beta secretasa.
BR112015012825A2 (pt) piridopirazinas substituídas como inibidores de syk
BR112012013319A2 (pt) derivados espiro azacíclicos
EA201391586A1 (ru) ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
UA109804C2 (xx) 2-метоксипіридин-4-ільні похідні
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
BR112013028945A2 (pt) novos compostos de hexahidropirroloimidazolona
BR112015022993A2 (pt) inibidores de jak2 e alk2 e métodos de uso dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2538 DE 27-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]